

# Conference Programme

16<sup>th</sup> & 17<sup>th</sup> May 2016  
Manchester Central



# BioVision

seeing more diagnostic quality...

## BioVision is the advanced, innovative Surgical Specimen Radiography System from faxitron

Immediate verification of excised breast tissue margins

Raises the standard of care for patients undergoing surgical excision core biopsy procedures

A completely mobile imaging unit designed to save time in the operating theatre and radiology

Distributed by

**daax**

T +44870 979 9110 info@daax.co.uk  
F +44870 979 9911 www.daax.co.uk



# MENTOR® CPG™ GEL BREAST IMPLANTS



10 YEARS THAT SHAPED BREAST AESTHETICS. CORE STUDY<sup>1</sup>



## TEXTURE YOU CAN TRUST

**PROVEN RESULTS THAT YOU CAN TRUST**  
By manufacturing an implant with our unique SILTEX™ Imprinted Texture, we have created a surface substantially free of pores and interstices<sup>2</sup> which can contribute to a reduction in key complications during breast augmentation.<sup>3,4</sup>

For further information about MENTOR® CPG™ Gel Breast Implants, talk to your Mentor Sales Representative or visit [mentor.wllc.eu](http://mentor.wllc.eu) for more information.

LOWEST	LOW	NO
Reported incidence of the following complications at 10 years <sup>1*</sup>	Complication risk in over 9000 SILTEX™ Texture Implants <sup>5</sup>	Silicone particulates left behind <sup>6</sup>
<b>3.8%</b> Capsular contracture in primary augmentation <sup>1</sup>	<b>0%</b> 0% reported double capsule based upon reported clinical studies <sup>1</sup>	<b>0 out of 5</b> No (0) particles suspected to be silicone globules were found in the capsular tissue of 5 patients implanted with SILTEX™ Texture devices <sup>6</sup>
<b>1.5%</b> Rotation in primary augmentation <sup>1</sup>		

\*Not a head to head comparison. Based on 10 year core clinical study reported data of CPG™ Gel Breast Implants, NATRELLE™ 410 Tru-Form™ 3 Gel Breast Implants, NATRELLE™ Round TruForm™ 1 Gel Breast Implants, and MemoryGel™ Breast Implants. These core clinical studies DID NOT include NATRELLE™ Inspira Round TruForm™ 1 Gel Breast Implants, NATRELLE™ 410 TruForm™ 2 Gel Breast Implants, or NATRELLE™ 510 Dual Gel Anatomical Breast Implants. Only clinical studies with 10 year data were considered.

1. Mentor Worldwide, LLC. MemoryShape® Post-Approval Cohort Study (formerly Contour Profile Gel Core Study) Annual Report. June 2014. 2. United States Patent Number 4,960,425. Yan et al. 3. Textured Silicone Breast Implant Use in Primary Augmentation: Core Data Update and Review. Brian M. Derby, MD, Mark A. Codner, MD. 4. Wixtrom R, Vargo J, Canady J. Controversies in Breast Implant Texturing: New evidence on friction, rotation, double capsules and interactive effect of device placement on contracture in primary augmentation. Paper presented at IQUM Congress and Consensus Conference. 10 April 2014. Budapest. 5. Mentor's Core and Continued Access studies for round and shaped breast implants. 6. Danino AM et al. Plast Reconstr Surg. 2001;108:2047-2052.



# President's Welcome

Welcome to Manchester the power house of the North: an appropriate venue for the 2016 ABS conference. Please sample everything this vibrant city has to offer but make sure you are at Manchester Central by 0900hrs sharp as this year's conference promises to be a winning combination: educational, edifying and entertaining.

The programme has been thoughtfully crafted by Mrs Katy Hogben and the ABS organising committee in response to suggestions and ideas from ABS members as well as current 'hot topics'. We hope the balance of sessions, ranging from service delivery, the role of the nurse practitioner, breast cancer management, altered body image, fertility, breast surgeon as patient, through to oncoplastic and aesthetic surgery reflects the interests of our members and is of value for all delegates.

Abstracts were plentiful and broad ranging demonstrating the high calibre of innovation, research, audit and practice in 'Breast UK'. Abstract marking is rigorous and independent and thanks must go to the council members and trustees who offered their time. If your abstract was not accepted this year then start preparing for 2017 - do not give up.

It is a particular pleasure to welcome our guest speakers from overseas: from Holland, Dr Poortmans, Professor of radiation oncology in Nijmegen and current president of ESTRO. His participation has allowed us to turn the spotlight on topical surgery/ radiotherapy issues. We hope to develop this theme further in the MDT meeting in January 2017. Dr Monica Morrow, breast surgeon at MSKCC, is a great friend of ABS and we are grateful for her time, erudition and commitment to improving breast surgery.

Please make the most of your time away from work so you can return refreshed, invigorated and brimming full of ideas to benefit your patients.

Many thanks.

A handwritten signature in blue ink that reads "Fiona MacNeill". The signature is written in a cursive, flowing style.

**Fiona MacNeill**  
ABS President



## No need to change your patient's lifestyle with Motiva

As a qualified Breast Surgeon you can provide the benefits of the next generation of breast implants, today.

- Q Inside Safety Technology™, state-of-the-art quality verification
- Full geometric design to **significantly reduce rippling and wrinkling**
- Exclusive warranty programme with **insurance backed cash payout**
- Non-abrasive **controlled Nanosurface** for active women
- Highly elastic ProgressiveGel™ Ultima: **no gel fracture with small incisions**
- Ergonomic design for **TrueTissue Dynamics™**

*The look and feel of*  
**Motiva Ergonomix™**  
*a natural breast*

Motiva TrueInnovation

[www.belle.org.uk](http://www.belle.org.uk)

[www.motivaimplants.com](http://www.motivaimplants.com)

[mail@belle.org.uk](mailto:mail@belle.org.uk)



## Magnetic Localisation and Molecular Analysis of SLN



Sentimag® for effective radioisotope free SLN localisation

- **Performance**  
Non-inferior to dual technique<sup>1</sup>
- **Flexibility**  
7 day injection window
- **Availability**  
Long shelf life, no half life
- **Efficiency**  
Optimised list management
- **Safety**  
No evidence of anaphylaxis



OSNA® for standardised determination of nodal burden

- Is Copy Number an indicator of patient outcome?  
**Visit us at Stand 5 to find out more**
- OSNA Copy Number:  
A better predictor than the number of positive LN<sup>2</sup>  
The only factor significantly correlated with  $\geq 4$  involved LN<sup>3</sup>
- Personalise treatment of SLNB positive patients (ALND or RT  $\pm$  CT)
- Post or intra-operative whole node analysis

[1] Teshome et al. (2016); Ann Surg Oncol. 23(5): 1508 – 14.  
 [2] Peg et al. (2013); Breast Cancer. Res Treat. 139: 87 – 93.  
 [3] Kubota et al. (2016); Mol and Clin Oncol. 4(2): 173 – 8.

[www.sysmex.co.uk](http://www.sysmex.co.uk)

Shaping the Advancement of Healthcare

**Distributor: Sysmex UK Ltd.** Sysmex House, Garamonde Drive, Wymbush, Milton Keynes, MK8 8DF, United Kingdom · Phone +44 870 9029210 · Fax +44 870 9029211 · [info@sysmex.co.uk](mailto:info@sysmex.co.uk) · [www.sysmex.co.uk](http://www.sysmex.co.uk)  
**Distributor: Sysmex Europe GmbH** Bornbarch 1, 22848 Norderstedt, Germany · Phone +49 40 52726-0 · Fax +49 40 52726-100 · [lifescience@sysmex-europe.com](mailto:lifescience@sysmex-europe.com) · [www.sysmex-europe.com](http://www.sysmex-europe.com)  
**Manufacturer Sentimag®: Endomagnetics Ltd.** The Jeffreys Building, Cowley Road, Cambridge CB4 0WS, United Kingdom  
**Manufacturer RD-100i: Sysmex Corporation** 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan · Phone +81 78 265-0500 · Fax +81 78 265-0524 · [www.sysmex.co.jp](http://www.sysmex.co.jp)

# ABS Conference

16th & 17th May 2016, Manchester Central

## Programme

### Monday 16th May 2016 – At a glance

	Exchange Auditorium	Exchange 8 - 10	Charter 2 - 3
09:00 to 10:30	<b>Session 1</b> Risk adapted radiotherapy	<b>Session 2</b> Nurse Practitioner roles	<b>Session 3</b> Submitted papers
<b>10:30 to 11:00 Tea and Coffee Break (Exchange Hall)</b>			
11:00 to 12:30	<b>Session 4</b> Delivering a quality service in today's NHS	<b>Session 5</b> BJS Papers	<b>Session 6</b> Inflammatory breast cancer
<b>12:30 to 14:00 Lunch Break (Exchange Hall)</b>			
12:30 to 13:15	<b>ABS AGM</b> (open to ABS members only)		
14:00 to 14:30	<b>Session 7</b> EJSO Lecture		
14:30 to 16:00	<b>Session 8</b> Aesthetic breast surgery	<b>Session 9</b> Submitted papers	<b>Session 10</b> Research: Where does surgery fit?
<b>16:00 to 16:30 Tea and Coffee Break (Exchange Hall)</b>			
16:30 to 18:00	<b>Session 11</b> NHS BSP & ABS Breast Screening Audit Session	<b>Session 12</b> Altered body image	
<b>18:00 to 18:45 Poster Viewing Session and Drinks Reception (Exchange Hall)</b>			

### Monday 16th May 2016

#### SESSION 1

##### 09:00 to 10:30: Exchange Auditorium

##### Risk adapted radiotherapy

*Chairs: Prof David Dodwell and Mrs Katy Hogben*

09:00 to 09:20	<b>Timing of post-mastectomy radiation therapy in relation to breast reconstruction</b> <i>Prof Philip Poortmans, Radboud university medical centre, Nijmegen, The Netherlands</i>
09:20 to 09:40	<b>IORT: An update</b> <i>Prof Michael Douek, Guy's &amp; St Thomas' NHS Foundation Trust</i>
09:40 to 09:55	<b>In which patients can radiotherapy be omitted?</b> <i>Dr Charlotte Coles, Addenbrooke's Hospital, Cambridge</i>
09:55 to 10:15	<b>Optimising radiotherapy after neoadjuvant chemotherapy</b> <i>Dr Andreas Makris, Mount Vernon Cancer Centre, Northwood</i>
10:15 to 10:20	<b>Marking the axilla after axillary dissection</b> <i>Mr Charlie Chan, Cheltenham Nuffield Hospital</i>
10:20 to 10:30	<b>Discussion</b>

**Monday 16th May 2016**

## **SESSION 2**

**09:00 to 10:30: Exchange 8-10**

### **Nurse Practitioner roles**

*Chairs: Mr Giles Cunnick and Ms Lis Grimsey*

<b>09:00 to 09:25</b>	<b>Setting up a Nurse Practitioner role</b> <i>Miss Anne McLoughlin, Royal Marsden Hospital, London</i>
<b>09:25 to 09:50</b>	<b>The role of the Surgical Nurse Practitioner</b> <i>Mrs Fiona Rabson, Buckinghamshire Healthcare NHS Trust</i>
<b>09:50 to 10:20</b>	<b>Documentation and legal issues</b> <i>Ms Lis Grimsey, East Sussex Healthcare NHS Trust</i>
<b>10:20 to 10:30</b>	<b>Discussion</b>

## **SESSION 3**

**09:00 to 10:30: Charter 2-3**

### **Submitted papers**

*Chairs: Miss Leena Chagla and Miss Anne Tansley*

<b>09:00 to 09:10</b>	<b>1. Identifying risk factors for low patient satisfaction with aesthetic outcome after breast conserving surgery (BCS)</b> <i>Ms Rachel O'Connell, The Royal Marsden NHS Foundation Trust, Sutton</i>
<b>09:10 to 09:20</b>	<b>2. Immediate lipofilling following breast conserving surgery for breast cancer is associated with improved patient reported cosmetic outcome</b> <i>Dr Lucy Khan, Edinburgh Breast Unit</i>
<b>09:20 to 09:30</b>	<b>3. Extreme oncoplastic surgery: extending the boundaries of breast conservation</b> <i>Ms Roanne Fiddes, Royal Hampshire County Hospital, Winchester</i>
<b>09:30 to 09:40</b>	<b>5. Patients are more satisfied after oncoplastic breast conservation than total autologous breast reconstruction</b> <i>Mrs Natalie Chand, Royal Hampshire County Hospital, Winchester</i>
<b>09:40 to 09:50</b>	<b>6. New possible surgical approaches for the submammary adipofascial flap based on its arterial supply</b> <i>Dr Ehab Elzawawy, University of Alexandria, Egypt</i>
<b>09:50 to 10:00</b>	<b>7. Recurrence and complications after volume replacement oncoplastic breast conservations</b> <i>Mr Laszlo Romics, New Victoria Hospital, Glasgow</i>
<b>10:00 to 10:10</b>	<b>8. Evaluation of the early post-operative effectiveness of a novel muscle-sparing breast reconstruction technique using Braxon® (acellular dermal matrix) - multicentre European experience</b> <i>Miss Raghavan Vidya, New Cross Hospital, Wolverhampton</i>

NB: Abstract 4 has been withdrawn

## **SESSION 4**

**11:00 to 12:30: Exchange Auditorium**

### **Delivering a quality service in today's NHS**

*Chairs: Dr Barbara Dall and Mr Kieran Horgan*

<b>11:00 to 11:20</b>	<b>The relationship of earlier presentation of symptomatic breast cancer to outcomes</b> <i>Dr John Graham, Musgrove Park Hospital, Taunton and Clinical Advisor to NICE Guideline Programme</i>
<b>11:20 to 11:40</b>	<b>"Getting it right first time": Lessons to be learned</b> <i>Prof Tim Briggs, Royal National Orthopaedic Hospital, Stanmore</i>
<b>11:40 to 11:55</b>	<b>Solitary Halt Visit – Redefining the Breast One Stop Clinic; for who, when and how?</b> <i>Miss Maria Bramley, Royal Oldham Hospital</i>
<b>11:55 to 12:20</b>	<b>Discussion</b>
<b>12:20 to 12:30</b>	<b>ABS' response</b> <i>Miss Fiona MacNeill, Royal Marsden Hospital, London</i>

**Monday 16th May 2016**

## **SESSION 5**

**11:00 to 12:30: Exchange 8 - 10**

### **BJS papers**

*Chairs: Prof John Benson and Mr Richard Johnson*

<b>11:00 to 11:10</b>	<b>9. Defining &amp; characterising cells derived from human lipoaspirate tissue - does the anatomical harvest site make any difference?</b> <i>Ms Mandana Pennick, Royal Liverpool Hospital</i>
<b>11:10 to 11:20</b>	<b>10. Development of a treatment pathway to improve quality of care in the management of breast abscess and mastitis</b> <i>Mr Findlay MacAskill, Imperial College Healthcare NHS Trust, London</i>
<b>11:20 to 11:30</b>	<b>11. The oncological safety of non-surgical management of close anterior margins in breast conserving surgery</b> <i>Mr George Boundouki, University Hospital of South Manchester</i>
<b>11:30 to 11:40</b>	<b>12. A comparison of two digital mammography systems at Breast Test Wales - more or less accurate?</b> <i>Ms Jennifer Long, Royal Glamorgan Hospital, Llantrisant</i>
<b>11:40 to 11:50</b>	<b>13. Should we MRI the contralateral breast in lobular cancer? A study from a teaching hospital and a District General Hospital</b> <i>Dr Jessica Tan, Hillingdon Hospital NHS Trust</i>
<b>11:50 to 12:00</b>	<b>14. The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients</b> <i>Dr Tim Rattay, University of Leicester</i>
<b>12:00 to 12:10</b>	<b>15. Axillary lymph nodes downstaging by neo-adjuvant chemotherapy for breast cancer</b> <i>Dr Samiya Al-Hattali, Ninewells Hospital, Dundee</i>
<b>12:10 to 12:20</b>	<b>16. Long term recurrence outcome of patients undergoing Oncotype DX testing for ER positive and node negative early breast cancer</b> <i>Mrs Saira Khawaja, Prince Philip Hospital, Llanelli</i>

## **SESSION 6**

**11:00 to 12:30: Charter 2 - 3**

### **Inflammatory breast cancer**

*Chairs: Mrs Clare Fowler and Mr Simon Harries*

<b>11:00 to 11:15</b>	<b>Why is there a need for an inflammatory breast cancer initiative?</b> <i>Miss Adele Francis, University Hospitals Birmingham NHS Foundation Trust</i>
<b>11:15 to 11:35</b>	<b>Standardisation of the management of inflammatory breast cancer</b> <i>Dr Daniel Rea, University of Birmingham</i>
<b>11:35 to 11:55</b>	<b>Inflammatory breast cancer pathology and tissue banking</b> <i>Prof Andrew Hanby, Leeds Teaching Hospitals NHS Trust</i>
<b>11:55 to 12:15</b>	<b>National audit of inflammatory breast cancer</b> <i>Dr Ellen Copson, Southampton General Hospital</i>
<b>12:15 to 12:30</b>	<b>Discussion</b>

## **SESSION 7**

**14:00 to 14:30: Exchange Auditorium**

### **EJSO Lecture**

*Chair: Miss Fiona MacNeill*

**Post mastectomy radiotherapy: Do we have all the answers?**

*Prof Philip Poortmans, Radboud university medical centre, Nijmegen, The Netherlands*

**Monday 16th May 2016**

## **SESSION 8**

**14:30 to 16:00: Exchange Auditorium**

### **Aesthetic Breast Surgery**

*Chairs: Mr Lee Martin and Miss Penny McManus*

<b>14:30 to 15:00</b>	<b>Mastopexy/augmentation techniques: How I do it</b> <i>Mr Paul Harris, Royal Marsden Hospital, London</i>
<b>15:00 to 15:10</b>	<b>ABS &amp; BSR imaging guidelines</b> <i>Ms Mandana Pennick, Royal Liverpool Hospitals &amp; St Helen's &amp; Knowsley NHS Trust</i>
<b>15:10 to 15:25</b>	<b>Imaging of breast implants</b> <i>Dr Alan Redman, Queen Elizabeth Hospital, Gateshead</i>
<b>15:25 to 15:35</b>	<b>Management of late implant seromas</b> <i>Mr Joe O'Donoghue, Royal Victoria Infirmary, Newcastle upon Tyne</i>
<b>15:35 to 15:45</b>	<b>Cosmetic Surgery Certification: What you need to know</b> <i>Prof Philip Drew, Royal Cornwall Hospital Trust</i>
<b>15:45 to 16:00</b>	<b>Discussion</b>

## **SESSION 9**

**14:30 to 16:00: Exchange 8 - 10**

### **Submitted papers**

*Chairs: Mr Charlie Chan and Mrs Maria Noblet*

<b>14:30 to 14:40</b>	<b>17. Local recurrence in young women with invasive breast cancer; The POSH study</b> <i>Mr Tom Maishman, University of Southampton</i>
<b>14:40 to 14:50</b>	<b>18. Managing the 'Angelina Jolie effect' with tea and biscuits</b> <i>Mrs Nicky Scott, Nottingham Breast Institute</i>
<b>14:50 to 15:00</b>	<b>19. First results of a pre-planned interim analysis of a national multicenter Patient Reported Outcome Study (PRO-Bra) in breast reconstruction following mastectomy with titaniferously coated polypropylene mesh (TilloopBra)</b> <i>Dr Stefan Paepke, Interdisziplinäres Brustzentrum der Technischen Universität München, Germany</i>
<b>15:00 to 15:10</b>	<b>20. Electrochemotherapy for skin metastases in advanced breast cancer: Experience from the London Cancer Network</b> <i>Mrs Shramana Banerjee, Royal Free London NHS Foundation Trust</i>
<b>15:10 to 15:20</b>	<b>21. An exploration of clinical decision-making in advanced nursing practice</b> <i>Mrs Suzanne Halliday, The Royal Marsden NHS Foundation Trust, Sutton</i>
<b>15:20 to 15:30</b>	<b>22. International validation of the EORTC Patient-Reported Outcome Measure (PROM) in breast reconstruction (BRR): Evaluating health related quality of life (HRQL) and clinical effectiveness</b> <i>Miss Zoë Winters, University of Bristol</i>
<b>15:30 to 15:40</b>	<b>23. Breast clinical nurse specialist perspective of decision support interventions</b> <i>Mrs Fiona Armitage, Royal Hallamshire Hospital, Sheffield</i>
<b>15:40 to 15:50</b>	<b>24. Comparison of treatment variations in old age breast cancer in two units of a metropolitan city in the United Kingdom</b> <i>Mr Laszlo Romics, New Victoria Hospital, Glasgow</i>



**Monday 16th May 2016**

## **SESSION 10**

**14:30 to 16:00: Charter 2 – 3**

### **Research: Where does surgery fit?**

*Chairs: Mr Ramsey Cutress and Prof Malcolm Reed*

<b>14:30 to 14:50</b>	<b>Breast Cancer Now research strategy</b> <i>Dr Simon Vincent, Assistant Director of Research Governance, Breast Cancer Now</i>
<b>14:50 to 15:00</b>	<b>iBRA Study update</b> <i>Miss Shelley Potter, University of Bristol</i>
<b>15:00 to 15:20</b>	<b>ABS Research Grants updates</b>  <b>Identifying research through public and patient perspectives and priorities (4Ps study)</b> <i>Mr George Boundouki for the North West Breast Trainees Collaborative</i>  <b>Magnetic occult lesion localization (MOLL) for non-palpable breast cancer</b> <i>Mr Muneer Ahmed, Guy's Hospital, London</i>  <b>Intra-operative rapid evaporative ionisation mass spectroscopy for oncological margin control in breast conserving surgery – towards an Intelligent Knife for breast cancer surgery</b> <i>Mr Daniel Leff, Imperial College London</i>  <b>Can text message reminders improve uptake of breast screening? A RCT</b> <i>Miss Sarah Huf, Imperial College London (joint grant with Genesis Prevention)</i>
<b>15:20 to 15:40</b>	<b>Debate: Surgeons should stick to surgical research</b> <b>For:</b> <i>Prof Michael Douek, Guy's &amp; St Thomas' NHS Foundation Trust</i>  <b>Against:</b> <i>Miss Cliona Kirwan, University Hospital of South Manchester</i>
<b>15:40 to 16:00</b>	Discussion

## **SESSION 11**

**16:30 to 18:00: Exchange Auditorium**

### **NHS BSP & ABS Breast Screening Audit session**

*Chairs: Mr Giles Cunnick and Mr Ashu Gandhi*

<b>16:30 to 16:40</b>	<b>Breast Screening Quality Assurance - new processes</b> <i>Mrs Olive Kearins, National Portfolio Lead for Breast Screening Quality Assurance</i>
<b>16:40 to 16:50</b>	<b>NHS Breast Screening Programme - new standards</b> <i>Mrs Jackie Jenkins, Programme Manager NHS Breast Screening Programme</i>
<b>16:50 to 17:00</b>	<b>Disclosure of audit and duty of candour in breast screening</b> <i>Dr Eleanor Cornford, Nottingham University Hospitals</i>
<b>17:00 to 17:05</b>	Discussion
<b>17:05 to 17:35</b>	<b>NHS BSP &amp; ABS Audit of screen-detected breast cancers 2014-2015</b> <i>Mr Mark Sibbering, Royal Derby Hospital</i>
<b>17:35 to 17:50</b>	<b>The future of NHS BSP &amp; ABS Audit of screen-detected breast cancers</b> <i>Mr Ashu Gandhi, University Hospital of South Manchester and Prof David Dodwell, Leeds Teaching Hospitals NHS Trust</i>
<b>17:50 to 18:00</b>	Discussion

**Monday 16th May 2016**

## **SESSION 12**

**16:30 to 18:00: Exchange 8 - 10**

### **Altered body image**

*Chairs: Prof Phil Drew and Ms Lis Grimsey*

<b>16:30 to 16:40</b>	<b>Flat friends: The patient's perspective</b> <i>Ms Gillian Cant</i>
<b>16:40 to 16:50</b>	<b>The choice to live flat without reconstruction: Patients', nurses' and surgical choice</b> <i>Mr Ash Subramanian, East Sussex Healthcare NHS Trust</i>
<b>16:50 to 17:10</b>	<b>The long term experience of risk reducing mastectomy for BRCA positive women, husbands and relatives</b> <i>Mrs Nicky West, Cardiff and Vale University Hospital Health Board</i>
<b>17:10 to 17:45</b>	<b>Perspectives on breast surgery in gender reassignment patients</b> <i>Dr John Dean, Devon Partnership NHS Trust</i> <i>Prof Philip Drew, Royal Cornwall Hospital Trust</i> <i>Mrs Sarah Zee, Royal Cornwall Hospital Trust</i>
<b>17:45 to 18:00</b>	<b>Discussion</b>

## **Tuesday 17th May 2016 - at a glance**

	<b>Exchange Auditorium</b>	<b>Exchange 8 - 10</b>	<b>Charter 2 - 3</b>
<b>09:00 to 10:30</b>	<b>Session 13</b> Fertility preservation in breast cancer patients	<b>Session 14</b> Submitted papers	<b>Session 15</b> Mammary Fold session

**10:30 to 11:00 Tea and Coffee Break (Exchange Hall)**

<b>11:00 to 11:30</b>	<b>Session 16</b> Invited Lecture		
<b>11:30 to 13:00</b>	<b>Session 17</b> Focus on: Familial breast cancer	<b>Session 18</b> Hot topics, trials and audits	<b>Session 19</b> Poster prize session

**13:00 to 14:00 Lunch (Exchange Hall)**

<b>14:00 to 14:30</b>	<b>Session 20</b> BJS Lecture		
<b>14:30 to 16:00</b>	<b>Session 21</b> Challenges following onco-plastic procedures	<b>Session 22</b> More hot topics	

**Tuesday 17th May 2016**

### **SESSION 13**

**09:00 to 10:30: Exchange Auditorium**

#### **Fertility preservation in breast cancer patients**

*Chairs: Mr Simon Cawthorn and Ms Siobhan Laws*

<b>09:00 to 09:20</b>	<b>Introduction</b> <i>Dr Alison Jones, Leaders in Oncology Care, London</i>
<b>09:20 to 09:40</b>	<b>Fertility options for patients with breast cancer – balancing hope and realistic expectation</b> <i>Mr Stuart Lavery, Hammersmith Hospital, London</i>
<b>09:40 to 09:55</b>	<b>Breast Cancer Care Fertility Toolkit</b> <i>Ms Grete Brauten-Smith, Breast Cancer Care, London</i>
<b>09:55 to 10:15</b>	<b>Case studies</b> <i>Dr Catherine Harper-Wynne, Maidstone and Tunbridge Wells NHS Trust</i>
<b>10:15 to 10:30</b>	<b>Discussion</b>

### **SESSION 14**

**09:00 to 10:30: Exchange 8 – 10**

#### **Submitted papers**

*Chairs: Mr Robert Kennedy and Mr Daniel Leff*

<b>09:00 to 09:10</b>	<b>25. Validation of the use of radioactive iodine-125 seed localisation of breast carcinoma in patients undergoing breast conservation surgery in the United Kingdom</b> <i>Mr Robert Milligan, Royal Victoria Infirmary, Newcastle</i>
<b>09:10 to 09:20</b>	<b>26. Locoregional recurrence following breast cancer surgery in the trastuzumab era: a systematic review by subtype</b> <i>Dr Andrew McGuire, NUI Galway, Ireland</i>
<b>09:20 to 09:30</b>	<b>27. Sentinel lymph node analysis pre and post introduction of One Step Nucleic Acid Amplification (OSNA): Cost evaluation</b> <i>Dr Madelaine Gimzewska, Ashford &amp; St Peter's NHS Foundation Trust, Chertsey</i>
<b>09:30 to 09:40</b>	<b>28. OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), a prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions</b> <i>Miss Adele Francis, University Hospitals Birmingham NHS Foundation Trust</i>
<b>09:40 to 09:50</b>	<b>29. London Cancer Alliance: Development of a metastatic breast cancer service model and service specification</b> <i>Ms Falguni Raja, London Cancer Alliance &amp; Northwick Park Hospital, London</i>
<b>09:50 to 10:00</b>	<b>30. Screen-detected lobular neoplasia of the breast: findings from the Sloane Project</b> <i>Dr Anthony Maxwell, University Hospital of South Manchester</i>
<b>10:00 to 10:10</b>	<b>31. Our initial experience of digital breast tomosynthesis guided vacuum assisted breast biopsies and the patient's perspective: A single center experience</b> <i>Mr Simon Holt, Prince Philip Hospital, Llanelli</i>
<b>10:10 to 10:20</b>	<b>32. Thrombin inhibition preoperatively (TIP) in early breast cancer (EBC), the first clinical trial of NOACs as an anti-cancer agent: Trial methodology</b> <i>Miss Cliona Kirwan, University Hospital of South Manchester</i>

**Tuesday 17th May 2016**

## **SESSION 15**

**09:00 to 10:30: Charter 2 - 3**

### **Mammary Fold Session**

*Chairs: Mr Baek Kim and Miss Chloe Wight*

<b>09:00 to 09:15</b>	<b>The future of general surgery</b> <i>Prof Jonathan Lund, Royal Derby Hospital</i>
<b>09:15 to 09:30</b>	<b>TIG fellowship curriculum update: What effect will the changes have?</b> <i>Mr Iain Mackay, Glasgow Royal Infirmary</i>
<b>09:30 to 09:45</b>	<b>Breast fellowship training in the US</b> <i>Dr Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, USA</i>
<b>09:45 to 10:15</b>	<b>From surgeon to patient: Lessons learned</b> <i>Miss Elizabeth Ball, Ipswich Hospital NHS Trust</i>
<b>10:15 to 10:30</b>	<b>Discussion</b>

## **SESSION 16**

**11:00 to 11:30: Exchange Auditorium**

### **Invited Lecture**

*Chair: Mr Mark Sibbering*

**Breast Screening: Past, present and future**

*Prof Julietta Patnick, Visiting Professor of Cancer Screening, University of Oxford*

## **SESSION 17**

**11:30 to 13:00: Exchange Auditorium**

### **Focus on: Familial breast cancer**

*Chairs: Mr James Harvey and Mr Philip Turton*

<b>11:30 to 11:50</b>	<b>Genetic testing in familial breast cancer: BRCA, panel &amp; SNP testing</b> <i>Prof Gareth Evans, Central Manchester University Hospitals</i>
<b>11:50 to 12:10</b>	<b>The medical management of the high risk patient</b> <i>Dr Sacha Howell, The Christie NHS Foundation Trust, Manchester</i>
<b>12:10 to 12:30</b>	<b>The role of clinical psychology in the family history team</b> <i>Dr Julie Wisely, Manchester Mental Health and Social Care Trust</i>
<b>12:30 to 12:50</b>	<b>Risk reducing mastectomy in high-risk women</b> <i>Mr Gerald Gui, Royal Marsden Hospital, London</i>
<b>12:50 to 13:00</b>	<b>Discussion</b>

## **SESSION 18**

**11:30 to 13:00: Exchange 8 - 10**

### **Hot topics, trials and audits**

*Chairs: Prof Michael Douek and Miss Adele Francis*

<b>11:30 to 11:50</b>	<b>What has the Sloane Project achieved and where to now?</b> <i>Prof David Dodwell, Leeds Teaching Hospitals NHS Trust</i>
<b>11:50 to 12:10</b>	<b>National Mastectomy Decisions Audit (MasDA) - A collaborative approach to understanding why mastectomies are performed in the UK</b> <i>Mrs Jagdeep Singh, Queen Elizabeth Hospital, Birmingham</i>
<b>12:10 to 12:25</b>	<b>ABS badged trials update</b> <i>Prof Malcolm Reed, Brighton and Sussex Medical School</i>
<b>12:25 to 12:45</b>	<b>Patient reported outcomes: Oncoplastic breast conserving surgery versus mastectomy and reconstruction</b> <i>Dr Jennett Kelsall, Nottingham City Hospital</i>
<b>12:45 to 13:00</b>	<b>Discussion</b>

Tuesday 17th May 2016

## SESSION 19

11:30 to 13:00: Charter 2 – 3

### Poster prize session

Chairs: Miss Cliona Kirwan and Mr Ash Subramarian

Presentation of the best 15 submitted posters

## SESSION 20

14:00 to 14:30: Exchange Auditorium

BJS

### BJS Lecture

Chair: Miss Julie Doughty

### Local therapy: When is less more?

Dr Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, USA

## SESSION 21

14:30 to 16:00: Exchange Auditorium

### Challenges following oncoplastic procedures

Chairs: Miss Karina Cox and Mr Nigel Mercer

14:30 to 15:15	<b>Tips and Tricks:</b> <b>The management of implant infections</b> <i>Mr John Scott, Glasgow Royal Infirmary</i>  <b>Cancer recurrence following breast reconstruction</b> <i>Mr Ashu Gandhi, University Hospital of South Manchester</i>  <b>Lessons learned after 6 years of ADM assisted breast reconstruction</b> <i>Mr Richard Johnson, University Hospital of South Manchester</i>
15:15 to 15:30	<b>Consent in oncoplastic procedures</b> <i>Mr Richard Sutton, Royal United Hospital, Bath</i>
15:30 to 15:45	<b>Avoiding litigation in oncoplastic procedures</b> <i>Mr Tim Davidson, Royal Free Hospital, London</i>
15:45 to 16:00	Discussion

## SESSION 22

14:30 to 16:00: Exchange 8 – 10

### More hot topics

Chairs: Mr Stuart McIntosh and Mr Mike McKirdy

14:30 to 14:50	<b>Bisphosphonates/denosumab for the treatment of early breast cancer: Do they increase survival?</b> <i>Dr Andreas Makris, Mount Vernon Cancer Centre, Northwood</i>
14:50 to 15:10	<b>Immunotherapy for surgeons</b> <i>Dr David Miles, Mount Vernon Cancer Centre, Northwood</i>
15:10 to 15:25	<b>Iodine seed localisation</b> <i>Mr Adam Critchley, Royal Victoria Infirmary, Newcastle upon Tyne</i>
15:25 to 15:45	<b>Neoadjuvant radiotherapy prior to mastectomy and immediate autologous reconstruction</b> <i>Mr Dimitri Hadjiminias, Imperial College Healthcare NHS Trust</i>
15:45 to 16:00	Discussion

# Invited Lecturers



## **Dr Monica Morrow**

Monica Morrow, MD is chief of the Breast Surgery Service, Anne Burnett Windfohr Chair of Clinical Oncology, co-chief of the Breast Program at Memorial Sloan-Kettering Cancer Center, and Professor of Surgery at Weill Medical College of Cornell University. Prior to this she served as the G. Willing Pepper Chair in Cancer Research and the chairman of the Department of Surgical Oncology at Fox Chase Cancer Center. From 1993 to June 2004, she was Professor of Surgery at Northwestern University Medical School and director of the Lynn Sage Comprehensive Breast Program at Northwestern Memorial Hospital. From 1999 - 2001 she also served as director of the Cancer Department of the American College of Surgeons and executive director of the American Joint Committee on Cancer. A native of Bucks County, Pennsylvania, Dr. Morrow received her BS degree Magna Cum Laude from the Pennsylvania State University in 1974 and her MD in 1976 from Jefferson Medical College. She did her surgical residency at the Medical Center Hospital of Vermont from 1976-1981, followed by two years of surgical oncology training at Memorial Sloan-Kettering Cancer Center in New York.

Dr. Morrow is the recipient of the Outstanding Professional Woman Award from the State of Illinois Federation of Business and Professional Women, the Alpha Omega Alpha Outstanding Clinical Faculty Award from the University of Chicago, the Women Making a Difference Award for Medical Innovations from the State of Illinois, and the Speaking of Women's Health Foundation Award. She is a Distinguished Alumni of the Pennsylvania State University and a Distinguished Alumni of Jefferson Medical College. In 2012 she was the recipient of the Gianni Bonnadonna Breast Cancer Award from ASCO, and in 2013 she was the William McGuire lecturer at the San Antonio Breast Cancer symposium. She is an Honorary Fellow of the Royal College of Physicians and Surgeons (Glasgow) and the Royal College of Surgeons of Ireland. She is the editor of three breast cancer textbooks and has published more than 350 book chapters, manuscripts, and editorials. She has served on the Board of Directors of the American Society of Clinical Oncology and the Society of Surgical Oncology, and was the President of the Society of Surgical Oncology in 2012-13. Her interests include the application of clinical trials data in practice, the evaluation of new technology related to local therapy of breast cancer and surgical decision making.



## **Professor Julietta Patnick CBE**

Julietta was responsible for overseeing the NHS Breast, Cervical and Bowel Cancer Screening Programmes and the Prostate Cancer Risk Management Programme until she left Public Health England in August 2015. She had first joined the NHS in 1979 and been involved in screening since the establishment of the Breast Screening Programme in 1987. She was appointed Visiting Professor in Cancer Screening at the University of Oxford in April 2008. She currently has research interests in colorectal cancer screening, cancer screening in general and is PI of the breast screening Age Extension trial which randomises about 500,000 women per year.



## Prof Philip Poortmans

In 1986 I completed my medical studies at the University of Antwerp. I was trained as a radiation oncologist at the Middelheim and Vincentius Hospitals in Antwerp under the supervision of Van den Bogaert c.s.

In 1991 I started as a radiation oncologist in Tilburg. Since August 2014 I chair the department of radiation oncology of the Radboud university medical centre, Nijmegen.

**Special interests:** breast cancer, quality assurance in clinical trials, malignant lymphoma and rare tumours.

**In 2005:** PhD thesis on quality assurance in clinical trials in breast cancer at the University of Maastricht.

**Since 1992:** Active in the EORTC, currently member of the Radiation Oncology (secretary 2006-2015), Lymphoma and Breast Groups; Quality Assurance Committee of the EORTC (2003-2015).

**2005 - 2008:** Councillor of the board of ESTRO.

**2007 - 2010:** Representative for radiation oncology in the Multidisciplinary Oncology Committee of ESMO.

**2013:** President-elect and, from 2014-2016, president of ESTRO.

ESTRO School of Radiotherapy and Oncology:

- Course director of the teaching courses “Multidisciplinary Management of Breast Cancer” and “Accelerated Partial Breast Irradiation”;
- Liaison person for all multidisciplinary courses;
- Core member of the Educational and Teaching Committee.

**2012:** “Technical Basis of Radiation Therapy. Practical Clinical Implications (Springer); co-edited with Levitt, Purdy and Perez.

Honorary membership of BVRO/ABRO since 2012, of ESSO since 2014 and of SEOR since 2015.

2011 and 2012 nominated as “Toparts” (Outstanding doctor) by the Dutch radiation oncologists.

**YOUR BREAST  
RECONSTRUCTION  
& AESTHETIC PARTNER**

**Acellular BioScaffold**  
**Meso BioMatrix®**  
Acellular Peritoneum Matrix  
by DSM

**A full range of  
Breast implants**

**Lipofilling solutions**  
**Fat Washer 800**  
macrofill

**3D Consultation**

**SEBBIN PARIS**  
ESTHETIQUE & RECONSTRUCTION

Recreating harmonious bodies for a new vision of rebirth.  
[www.sebbin.com](http://www.sebbin.com)

Sebbin UK Ltd: Tel.: 0800 652 4028 - Fax: +4433 0088 9575 - Email: [custserv@sebbin.uk](mailto:custserv@sebbin.uk)

# List of Exhibitors

## Trade Exhibition

The Exhibition will be held in the Exchange Hall and will be open at the following times:

**Monday 16th May 2016:** 07:45 to 19:00

**Tuesday 17th May 2016:** 08:30 to 14:00

---

### Allergan Ltd

Allergan is a unique, global pharmaceutical company, focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products. We have a specialist focus on central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular, anti-infective therapeutic categories as well as a commitment to biosimilars. With commercial operations in approximately 100 countries, Allergan is committed to working with our customers to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

---

### Belle

Motiva® is a range of latest generation breast implants created with safety in mind. Motiva's technological advances including world first, nano-surfaced implants, BlueSeal® visible barrier layer and Q inside Safety Technology™ have led to dramatically reduced complication rates with capsular contracture Baker grade III/IV and rupture both less than 1% at 5 years. Come and talk to use about how Motiva can help you to provide better outcomes for your patients. While you're here why not ask about MicroAire's Power Assisted Lipoplasty system and LipoFilter large volume fat transfer system.

---

### Breast Cancer Care

Breast Cancer Care is the only UK-wide charity providing specialist support and tailored information for anyone affected by breast cancer. Our clinical expertise and emotional support network help many thousands of people find a way to live with, through and beyond breast cancer.

[www.breastcancercare.org.uk](http://www.breastcancercare.org.uk) • Helpline: 0808 800 6000 • Twitter: @BCCare

---

### Breast Cancer Now

Breast Cancer Now is the UK's largest breast cancer charity, created by the merger of Breast Cancer Campaign and Breakthrough Breast Cancer. We're bringing together the brightest minds to discover how to prevent breast cancer, how to detect it earlier and how to treat it effectively at every stage. We're the catalyst that connects the laboratory bench with the hospital bedside, the GP's office, the MP's surgery and the policies that govern our health service. We make the voices of patients and their families heard, and support the health service to champion their needs. If we all act now, by 2050, we believe everyone who develops breast cancer will live.

---

### Care Wise

Southern Scientific Ltd acquired Care Wise in 2015. Previously the European distributor of the company's gamma probe systems, Southern Scientific has many years of experience and expertise working with the product range. Also part of the LabLogic group, the company is a key supplier to the healthcare sector worldwide.

Our products include:

C-Trak Galaxy Gamma Probe System which provides accurate and precise detection of radiation for use during sentinel node biopsies in breast, melanoma and other types of cancer.

C-Trak Auto Analyser which is designed to maximize background radiation correction and give high sensitivity for locating the lymph nodes.



# List of Exhibitors

---

## Cook Medical

We won't be satisfied with the state of surgery until every person who enters the operating room has a positive outcome. We've been working toward that goal by partnering with surgeons, sharing advanced techniques, and making devices that can help in even the most complex cases.

In 1963, Cook Medical's founder, Bill Cook, worked with a surgeon to launch the field of minimally invasive medicine. Now we continue his vision worldwide, through educational programs like Cook Vista and through technology like Biodesign and Zenapro.

Our goal is to deliver devices that give the best outcomes to surgeons, hospitals, and - most importantly - patients.

Learn more about us at [www.cookmedical.eu](http://www.cookmedical.eu)

---

## DAAX Ltd

UK/ Ireland representatives of FAXITRON - leading manufacturers of innovative solutions for digital specimen radiography.

**BioVision** for surgical radiography enabling a surgeon to accurately determine margin assessment within 10 seconds minimising the risk of re-excision and saving at least 20 minutes per procedure

**CoreVision** for breast care units to identify calcification within needle biopsy

**PathVision** for histopathology where the large field of view provides imaging capability from small wax block assessment to full mastectomy and fetal specimen imaging.

"Vision" systems - simple to operate providing clinicians with an unique level of image quality.

For information visit: [www.daax.co.uk](http://www.daax.co.uk)

---

## FAHRAS

FaHRAS supplies a sophisticated evidence-based software system which enables a user to run a variety of analyses against their family history to quantify their risk of developing breast cancer.

---

## GC Aesthetics

GC Aesthetics understand women today. We're a vibrant, global organisation in touch with both women's needs, their wellbeing and aspirations. It's our mission to become the leading female medical and breast implant provider.

Put simply, we want to empower women to change the way they feel about themselves by developing innovative products and supplying them with care.

Through our two leading brands - Nagor and Eurosilicone - we've decades of market presence and experience in breast implants and have developed:

- A strong reputation for safety, quality and reliability
  - Innovative product design features as a result of focused research and development for breast reconstruction surgery.
  - A differentiated approach to marketing and customer service focusing on women's needs.
- 

## GeneHealth UK

GeneHealth UK is the UK's leading provider of private genetic counselling and testing. There has been a significant increase in awareness around inherited breast cancer thanks to celebrities in recent years, and with new genetic technology and insurance companies covering some genetic testing, the general population is today well informed about the availability of tests such as BRCA1 and BRCA2. Our turnaround times are 2-4 weeks for BRCA 1&2 and approx. 10 weeks for our BreastGene Panel test. If you would like to work with us to provide affordable, state of the art genetic testing with counselling, then please visit us on stand no. 2.

---

## Genomic Health

The company's flagship product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in ductal carcinoma in situ (DCIS). With half a million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalised medicine by making genomics a critical part of cancer diagnosis and treatment. Genomic Health's UK office is located in London.

# List of Exhibitors

---

## Healthcare 21

Healthcare 21 are delighted to be a Corporate Sponsor of ABS and join you in Manchester. On display at our booth will be the Lifecell® regenerative medicine portfolio including Strattice® reconstructive tissue matrix, Prevena® incision management system and the new Revolve® fat processing system. Healthcare 21 are Acelyty's exclusive sales and marketing partner for Lifecell® products in the UK, Ireland, Germany and Austria. We were established in 2003 and are now one of the UK and Ireland's largest privately owned healthcare companies. We look forward to meeting you and introducing some of our new ADM products that will be in the UK soon.

---

## IGEA Medical

Through extensive research IGEA have developed CLINIPORATOR™ to deliver electrochemotherapy. It has been well documented that cutaneous metastases have the greatest impact on a patient's day to day quality of life. CLINIPORATOR™ offers patients with cutaneous and subcutaneous metastases an option to improve quality of life when perhaps other treatments have been exhausted.

---

## Independent Cancer Patients' Voice

Independent Cancer Patients' Voice is a patient advocate group led by patients for patients. We bring the views and experience of cancer patients, their families and carers, to the cancer research community. We believe that clinical research benefits from patients being partners with clinical researchers - rather than passive recipients of healthcare. Our aim is to improve existing treatments for every cancer patient and develop new treatments by bringing the patients' voice into clinical research. Our members are involved in the design and/or sit on the board of at least one clinical trial.

---

## Joint Operations

Joint Operations work in partnership with one of the largest tissue banks in the world to provide unique Allograft solutions in breast reconstruction, plastics and burns. Our unique Human Derived Acellular Dermal Matrix offers a viable alternative to traditional xenograft meshes.

Our partners, Allosource, are a non for profit organization with over 20 years' experience providing Allografts around the world. With an outstanding safety record and a commitment to honour the gift of donation, making Allosource Allografts the perfect choice.

---

## Lightpoint Medical

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's ground-breaking molecular imaging technology has the potential to detect cancer in real-time during surgery and thereby reduce the need for repeat operations.

Today, surgeons primarily rely on visual and tactile assessment to find cancerous deposits. The Lightpath™ Imaging System is designed to fill this important medical need. By providing a means to assess tumour status intra-operatively, via molecular imaging, it aims to enable surgeons to know with confidence that they have removed all cancerous tissue.

---

## LS BioPath

LS BioPath develops innovative intra-operative diagnostics to improve the success rate of cancer removal surgeries. LS BioPath leverages its core competence in semiconductor technologies and manufacturing to develop real-time, mobile, miniature and easy to use devices. Our first product **ClearEdge™** imaging device, uses bio-impedance spectroscopy to assess cellular tissue characteristics. Its first clinical use is obtaining clear tissue margins in breast conserving cancer surgeries by guiding surgeons to quickly and precisely localize abnormal tissue.

---

## Medtronic Ltd

Medtronic partners with medical professionals to develop life-changing technologies that improve the way chronic diseases are treated. Medtronic Advanced Energy is dedicated to developing technology that improves outcomes for doctors and their patients. Our electrosurgical products are designed to assist surgeons during a variety of procedures, including orthopaedic, spinal, surgical oncology, plastic/ reconstructive and ENT applications. The PEAK® Surgery System is a new tissue dissection system that represents an important advance in radiofrequency (RF) surgical technologies. PEAK PlasmaBlade devices offer the precision of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral tissue damage.

# List of Exhibitors

---

## Mentor

As a world's leading manufacturer of breast implants, Mentor is delighted to be associated with ABS' exciting agenda. With aesthetic and reconstructive surgery never far from the public spotlight, we realise just how crucial these opportunities are to understand best practice and gain consensus. We look forward to the debates, solutions and expertise shared during this meeting. On behalf of Mentor, we wish you the very best for the conference.

---

## Oncology Systems Limited (OSL)

Oncology Systems Limited specialises in supplying radiotherapy technology for the treatment of cancer and is the exclusive distributor of the Carl Zeiss INTRABEAM system throughout the UK and Ireland. Although primarily used for the treatment of breast cancer at the time of breast conserving surgery (TARGIT), potentially negating the need for several weeks of external beam radiotherapy treatment, the INTRABEAM system also has applications in the following areas: head and neck, colorectal, kypho, GYN and superficial. Stop by the OSL booth to find out more.

Email: [enquiry@osl.uk.com](mailto:enquiry@osl.uk.com) • Telephone number: +44 (0) 1743 462694 • Website: [www.osl.uk.com](http://www.osl.uk.com)

---

## Oncotherapy Resources Ltd

Oncotherapy Resources Limited (ORL) specialises in Single Dose Intra-operative Radiotherapy (SD-IORT) for early breast cancer patients delivered at the time of breast conserving surgery that for carefully selected patients can often remove the need for 3 weeks of external beam radiotherapy. SD-IORT is delivered as part of a fully managed, mobile service on a fee per patient treated basis and available at Spire, Nuffield and BMI hospitals nationally.

---

## Operating Room Systems Ltd

Operating Room Systems Ltd., specialise in the supply of surgical equipment and associated consumables to hospitals and private clinics across UK and Ireland. Our product portfolio spans across the clinical spectrum with particular specialism within the area of Minimally Invasive Surgery.

Within Breast Surgery we offer a range of solutions for effective retraction combined with delivery of light to the operative field. As sole distributor for World of Medicine, we represent Gamma Finder® in this market. The Gamma Finder® probe is best suited for Sentinel Node and Parathyroid Localization in Surgical Oncology. Its unique design puts simplicity and accuracy at the surgeon's fingertips. The Gamma Finder® probe will detect and give a numerical indication and an acoustic signal when in proximity of a gamma ray emitting source. Compact, lightweight and versatile, the Gamma Finder® probe is easily transported from operating room to operating room in its own sturdy carry case.

Our philosophy at Operating Room Systems is clear. We are committed to building long term sustaining relationships with our customers, bringing them innovation, value and quality; along with delivering effective technical support and robust after sales service provision.

---

## pfm medical UK Ltd

pfm medical UK Ltd is the UK subsidiary of pfm medical ag.

We are specialist manufacturers and distributors of vascular access, wound drainage, histology and surgical implant (titanized mesh) products. Located in the Cheshire countryside, we are committed to supplying high quality products to the NHS, private hospitals, research and development centres, laboratories, veterinary surgeries, pharmaceutical and all other care services.

We have been established since 2007 and have a strong team of clinical sales consultants and expert support staff.

---

## Q-Surgical Ltd

Q-Surgical supplies the surgical marketplace with innovative products. Vector paints and clips used to clearly identify tissue margins and Quill barbed, knotless sutures which save OR time and eliminate the use of drains. We pride ourselves in our clinical knowledge and strive to promote the best patient care.

# List of Exhibitors

---

## Q Medical Ltd

Q Medical Technologies Ltd is an independent UK company founded in 2004. The company exclusively distribute a hand-picked range of innovative medical devices.

The unique innovative range include:

- Polytech Microthane Breast Implants
- SurgiMend ADM for abdominal wall reconstruction and breast reconstruction
- Ellman Radio Frequency surgical units
- Accuvein vein viewers
- Pain relieving products

Contact us for more information:

Telephone: 0845 194 9284 • Fax: 0845 0949380 • E-mail: [info@qmedical.co.uk](mailto:info@qmedical.co.uk)

---

## Raise Healthcare

Raise Healthcare is an exclusive distributor for a range of Biologic (Acellular Dermal Matrix) meshes for UK market. Manufactured in Germany, our products include NATIVE and BRAXON - for Breast Reconstruction.

NATIVE - Porcine derived, freeze dried ADM for Sub-Pectoral Breast Reconstruction available in various sizes.

BRAXON - an innovative, first ever ADM for Muscle Sparing Breast Reconstruction for complete coverage of the Breast implant without detaching the Pectoralis Muscle.

For more information please visit us in exhibition hall or email [enquiries@raisehealthcare.co.uk](mailto:enquiries@raisehealthcare.co.uk)

---

## RioMed Ltd

Software development in healthcare is the primary focus of RioMed Ltd. It is a privately owned software development house which operates in the healthcare industry designing and producing software applications for use across the health sector.

Since 1997, RioMed has been delivering world class software solutions to major healthcare organisations such as the NHS and Ministries of Health across the UK, the Republic of Ireland and the Caribbean and is currently providing clinical software to over 150 British and Irish sites.

RioMed is an international company, with HQ in the UK and regional offices in Trinidad & Tobago and India.

---

## Roche

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-eight medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

Roche in the UK employs over 2,000 people in pharmaceuticals and diagnostics. For more information: [www.roche.co.uk](http://www.roche.co.uk)

---

## Sebbin UK Ltd

Groupe SEBBIN designs, manufactures and markets silicone implants dedicated for aesthetic and reconstructive surgery and has done so for the last 30 years. Product portfolio includes breast implants with more than 400 options in round and anatomical shapes, with smooth, microtextured or textured envelope. Tissue expanders of various shapes and custom made implants based on 3D technology as well as single use kits and devices for lipofilling procedures.

Group SEBBIN also markets and distributes Meso BioMatric® an Acellular Peritoneum Matrix designed and developed by DSM specifically for breast reconstruction. Groupe SEBBIN is present in nearly 60 countries through its distribution network and also direct through its subsidiaries Belgium, Germany, Switzerland and Spain. In June 2015 we launched a new branch in the UK to provide your patients with innovative solutions, whilst delivering a first class service.

# List of Exhibitors

---

## Smith & Nephew

Smith & Nephew is a diversified advanced medical technology business that supports healthcare professionals in more than 100 countries to improve the quality of life for their patients. We do this by taking a pioneering approach to the design of our products and services, by striving to secure wide access to our diverse technologies for more customers globally, and by enabling better outcomes for patients and healthcare systems. Smith & Nephew provide a range of products for preventing, treating and managing wounds.

[www.smith-nephew.com](http://www.smith-nephew.com) • E-mail: [advice@smith-nephew.com](mailto:advice@smith-nephew.com)

---

## Sysmex UK Ltd

Is OSNA Copy Number an indicator of patient outcome? Visit us at Stand 5 to find out more!

Sysmex continues to strive to improve cancer treatment with advanced technologies. OSNA remains the only system approved by NICE for SLN analysis with more than 100,000 patients already benefitting from this approach. Accurate standardised whole node staging of patients is achieved utilising the OSNA copy number as the predictive tool for appropriate axillary clearance. The Sentimag System is non inferior to the dual technique and proven for accurate localisation of SLN during surgery and without the requirement for radioisotope or blue dye.

[www.sysmex-lifescience.com](http://www.sysmex-lifescience.com)

---

## Thamert UK

Thamert (UK) Ltd is proud to present their 2016/17 range of Silima® breast forms, including the latest state-of-the-art soft and lightweight silicone technology in Silima® optima, a good choice of fibrefill post-op 'softies' offering value for money, and stylish and supportive bras at affordable prices for patients and hospitals. Our service provision - both office and field based - is second to none. We employ caring and helpful support staff, as well as competent and experienced product specialists, who assist with any product needs or fitting requests that our Breast Care Nurse customers may have. Please contact us for information, help or requests for stock.

---

## Theraclion

Theraclion is a French company specialized in leading edge medical equipment for echotherapy. Theraclion has designed and manufactured an innovative solution for using therapeutic ultrasound allowing non-invasive tumour treatment through US guided high intensity focused ultrasound. Theraclion is ISO 13483 certified and has received CE mark for breast fibroadenomas and thyroid nodules treatment.

---

## Trulife

In 1958 Trulife developed what would become the world's first breast prosthesis. We continue to lead through innovation by creating the most natural and beautiful breast forms available. This ethos remains at the heart of everything we do at Trulife. We understand the importance of restoring confidence and self-esteem and consequently improving the quality of life for women following breast surgery. We understand because we listen and have been listening for over 50 years.

---

## UK National Flap Surgery Registry

Dendrite Clinical Systems is a specialist provider of clinical database systems for hospitals and national registries. In collaboration with BAPRAS and ABS, Dendrite is very pleased to announce the launch of the UK National Flap Surgery Registry. If you are a breast reconstruction surgeon, please visit our exhibition stand to see how the software works and register to join the database.

Dendrite Clinical Systems Ltd, The Hub, Henley-on-Thames, Oxfordshire RG9 1AY

Tel: 01491 411 288 • Fax: 01491 411 377 • Email: [info@e-dendrite.com](mailto:info@e-dendrite.com) • Website: [www.e-dendrite.com](http://www.e-dendrite.com)

---

## UK Surgical Ltd

Privately owned company specializing in manufacturing self retracting retractor systems and devices for oncological surgery. We also bespoke surgical instruments that make a difference. Please stop by our stand.

# List of Exhibitors

---

## University of East Anglia

SCM is UEA's award-winning Specialist Clinical Mastership in Oncoplastic Breast Surgery - Europe's highest postgraduate qualification delivered by some of the UK's leading surgeons. SCM offers the most flexible training solution for the training needs of busy oncoplastic breast surgeons.

Teaching is delivered via our dedicated VLE, which hosts a thriving online community of specialists from all over the world. EU or UK student will also attend face-to-face training days with tutors every 16 weeks. This course promises to boost consultant-level thinking with each module, to develop greater confidence in MDTs and communication with peers and senior colleagues.

---

## Wake Medical Ltd

Wake Medical Ltd is the UK and European supplier of the First Sensor Cordless Gamma Probe. Developed and manufactured in Berlin; providing the latest sensor technology in gamma probes.

---

## Womanzone Ltd

With over 50 year experience we can offer an unrivalled service of care and advice including free fitting, made to measure swimwear and pocketing services.

---

**The ABS would like to thank all the companies exhibiting for their support of the meeting**

**Webcasts of most of the presentations from the conference will be available shortly on the ABS website:**



**[www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)**

# Surgeries for ABS Members

*The ABS is aware that many of their members have issues they wish to raise with the Trustees during the ABS Conference. In order to provide a proper forum for these discussions the ABS is providing four themed surgeries during the ABS Conference for its members.*

There will be **three** open forum surgeries, which will be Q & A sessions, as follows:

## **Nursing Issues**

Monday 16th May 2016  
13:15 to 14:00  
Exchange 2 - 3  
with Lis Grimsey

## **Education and Training**

Monday 16th May 2016  
18:00 to 19:00  
Exchange 2 - 3  
with Julie Doughty and Katy Hogben

## **Service Delivery**

Monday 16th May 2016  
18:00 to 19:00  
Exchange 8 - 10  
with Simon Cawthorn and Kieran Horgan

These surgeries will be open to ABS members only. Please note that if the room capacity is reached members may not be able to join the meeting.

There will also be an **additional** closed surgery as follows:

## **Professional Issues**

Tuesday 17th May 2016  
08:30 to 10:00  
Exchange 2 - 3  
with Fiona MacNeill and Mark Sibbering

There will be six individual 15 minute slots available for members wishing to attend this surgery. These need to be booked in advance. Please see Lucy Davies at the registration desk to book an appointment.

The Trustees want to understand what professional concerns are engaging ABS members and see if there are any common themes that need to be addressed at a wider level through the organisation's activities and CPD.

As senior, experienced clinicians they are pleased to listen and support members with any professional issues in a friendly, collegiate manner. The Professional Issues surgery will be confidential and the opinions and any advice offered in it will be personal. The aim will be to signpost solutions.

The ABS Trustees cannot become involved in on-going employment disputes, legal or GMC fitness to practice issues nor is the ABS the appropriate body to report concerns around patient safety or colleagues' fitness to practice.

# General Information

## Registration Desk

Registration will be open in the Exchange Foyer at the following times:

Monday 16th May 2016: 07:45 to 19:00

Tuesday 17th May 2016: 08:30 to 16:15

## Lunch and Refreshments

Lunch and refreshments will be served in the Exchange Hall at the times listed in the programme.

## A/V Preview Room

An A/V Preview Room is available in Exchange Room 1 for the duration of the meeting. Speakers are requested to hand their presentations into the room on arrival.

## Posters

The poster presentation will be displayed in the Exchange Hall for the duration of the meeting. Please can all poster presenters mark and store their poster tubes in the boxes provided in the room. These will be stored at registration. Posters should be removed between 13:45 and 14:00 on Tuesday 17th May and can be stored at registration for the afternoon session if required. Posters left on the boards after this time will be removed and the ABS cannot accept responsibility for their safe return.

## Cloakroom

A cloakroom and luggage store will be available in the Exchange Foyer for the duration of the meeting.

## Security

In the interests of security, delegates are required to wear their name badges at all times during the meeting.

## Wi-fi

To access Manchester Central's free Wi-Fi connect to MCCC wireless network, then click "Login to Manchester Central's Free Wi-Fi".

## Prayer Room

A prayer room is available for the use of delegates. Please ask at registration for details.

## Photography

A photographer will be taking images of the conference on Monday 16th May for use by the ABS at this meeting, in publications and on its website. If you do not wish to have images of yourself used by the ABS please let Lucy Davies know by email at: [lucydavies@absghi.org.uk](mailto:lucydavies@absghi.org.uk)

## ABS Annual Dinner

The ABS Annual Dinner will be held on Monday 16th May 2016 in Charter 1 - 3 at Manchester Central. Please return to the venue via the Charter Foyer for the Annual Dinner. Attendees must have bought a ticket in advance of the event. Dress is lounge suits.

## Texting questions in the Exchange Auditorium

Delegates in the Exchange Auditorium can text their questions to the session chairs. Text your questions to 60777 and prefix your message with 'ABS'. Please include your name and unit with your message.

## CPD

The two day meeting has been awarded 12 CPD points by the Association of Surgeons of Great Britain and Ireland.

A CPD certificate has been issued to you with your name badge. Please ensure that you retain this as duplicates cannot be provided.



## Twitter

You can follow the ABS on Twitter @ABSGBI. Please tweet during the ABS Conference using the hashtag #ABSMC2016 to be included in the Twitter Feed.



# Notes

Lined area for writing notes, consisting of numerous horizontal blue dotted lines.

# **4th ABS Multidisciplinary Meeting: Breast reconstruction and radiotherapy**

16th January 2017 • Queen Elizabeth II Centre, London



See [www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk) for further details in due course

## **DIARY DATE**

### **ABS Conference**

15th & 16th May 2017 • Belfast Waterfront



Photo courtesy of Todd Architects

**This meeting is supported by the  
Association of Breast Surgery's sponsors:**



This event has been sponsored by Roche Products Ltd who have contributed to stand costs but who have had no involvement in any other arrangements for this meeting.



Association of Breast Surgery  
at The Royal College of Surgeons  
35 – 43 Lincoln's Inn Fields  
London WC2A 3PE

**T** 020 7869 6853  
**F** 020 7869 6851  
**E** [office@absgbi.org.uk](mailto:office@absgbi.org.uk)  
**W** [www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)